News
Eltrombopag irons out kinks in hematopoiesis
The thrombopoietin-receptor agonist’s iron-chelating action stimulates hematopoietic stem cell activity, independent of the thrombopoietin...
News
Posttherapy HPV DNA a bad omen in cervical cancer
Women with detectable plasma human papillomavirus DNA at the end of chemoradiation were at increased risk for recurrence.
News
Fatal toxicities from checkpoint inhibitors vary by agent
Cardiac and neurologic toxicities accounted for nearly half of all toxicities associated with cancer therapy with immune checkpoint inhibitors.
News
AKT inhibitor exhibits activity against MM
Preclinical research suggests an AKT inhibitor could be effective against multiple myeloma (MM). The inhibitor, HS1793, is a derivative of the...
News
CRP levels may augur RCC prognosis
Patients with renal cell carcinoma who had higher serum levels of C-reactive protein had worse cancer-specific survival.
News
Sequencing informs prognosis after HSCT in MDS
Gene sequencing early after transplant may provide important prognostic information in patients with myelodysplastic syndromes (MDS), according to...
News
Osteonecrosis of jaw in mRCC higher with denosumab/antiangiogenics
Of 41 patients with metastatic kidney cancer treated with denosumab and a tyrosine kinase inhibitor, 7 developed osteonecrosis of the jaw.
News
Skin signs may be good omens during cancer therapy
Vitiligo, rash, nail changes, and other cutaneous toxicities are associated with good clinical outcomes with three major classes of cancer...
News
Novel AKT inhibitor active against MM cells
The investigational agent showed multiple myeloma-specific cytotoxicity in human cells, and antimyeloma activity in mouse models.
News
MDS posttransplant gene sequencing prognostic for progression
The presence of one or more mutations with higher maximum variant allele frequency 30 days after transplant heralded worse outcomes.
News
Outcomes similar for concurrent versus sequential treatment in HER2-positive breast cancers
Long-term results of a phase 3 trial indicate that concurrent FEC, paclitaxel and trastuzumab is not warranted, investigators say.
News
FILM: Rave review for indocyanine green in lymphatic mapping
Fluorescent indocyanine green under near infrared spotted significantly more lymph nodes in patients with cancer than isosulfan blue under white...
News
ESMO scale offers guidance on cancer targets
The ESMO Scale of Clinical Actionability for Molecular Targets is intended to help oncologists prioritize therapeutic targets detected on gene...
News
MRI doubles rate of observation in low-risk prostate cancer
The findings could enhance confidence in observation/active surveillance as a management strategy for men with low-risk prostate cancer.
News
Patients with mRCC survive longer at high-volume centers
Survival outcomes were better for patients treated at centers caring for a mean of 20 patients per year compared with 5 or 10 per year.